The pooled data showed that low/negative expression of TYMS was associated with a significant median survival advantage in advanced NSCLC patients receiving pemetrexed-based regimen(HR 0.41, 95%CI [0.22, 0.78] P=0.007; Figure 6). This evidence concerns the gene TYMS and non-small cell lung carcinoma.